Dr. Schadendorf on the Efficacy of Targeted Therapy Plus Checkpoint Inhibitors

Dirk Schadendorf, MD
Published: Saturday, Oct 21, 2017



Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses the efficacy of combining targeted therapy with checkpoint inhibitors for patients with melanoma.

There has been great progress in treating advanced melanoma, states Schadendorf. Checkpoint blockade has made contributions, giving long duration of responses and a median overall survivial of 3 years.
<<< View more from the World Congress of Melanoma


Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses the efficacy of combining targeted therapy with checkpoint inhibitors for patients with melanoma.

There has been great progress in treating advanced melanoma, states Schadendorf. Checkpoint blockade has made contributions, giving long duration of responses and a median overall survivial of 3 years.
<<< View more from the World Congress of Melanoma

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x